glp-1 agonists names Best Med #2: Receptor — vim Performance Medicine GLP-1’s (incretin mimetics), This type

The SELECT trial was the first large, randomized study to show that a drug used for obesity could reduce cardiovascular disease, says Isaacs

doi: 10.1016/j.nlm.2010.02.002 56 BenedictCHallschmidMHatkeASchultesBFehmHLBornJet al

Compounded drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs

28, w822w831

D., Brand, C

In the Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction with Obesity (SUMMIT) trial, tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure events in patients with heart failure with preserved ejection fraction (ejection fraction 50% and above) and obesity (BMI 30 kg/m 2 ), compared with placebo (HR 0.62